Contact Us

The choice depends on whether you are studying HGF (hepatocyte growth factor)'s role as the c-MET (HGFR) ligand or modeling its autocrine/paracrine functions in cancer and tissue regeneration. The Knockout line is the standard tool for asking whether HGF is required for autocrine c-MET signaling — HGF is a 90 kDa secreted heterodimeric growth factor (α and β chains processed from a single precursor) that binds c-MET receptor tyrosine kinase with high affinity, driving PI3K-AKT, MAPK, and other downstream signaling for cell proliferation, motility (scattering), and survival. Overexpression is useful for studying HGF gain-of-function effects. For HGF-MET pathway research, the EDITGENE HGF Knockout in HEK293 enables study of autocrine HGF production. Rescue with wild-type or proteolytic-cleavage-deficient HGF (HGF requires HGF activator/HGFA cleavage between the α and β chains for biological activity) enables structure-function studies. The knockout is valuable for studying HGF-MET autocrine signaling, MET-targeted cancer therapeutics (capmatinib, tepotinib, savolitinib FDA-approved for METex14 NSCLC; anti-HGF antibody rilotumumab in development), and HGF's role in liver regeneration and fibrosis.

Yes. HGF rescue experiments require attention to secreted heterodimeric growth factor processing: • Construct design: HGF is a secreted protein processed from a single precursor into α and β chains held by disulfide bonds — N-terminal tag (after signal peptide) is preferred over C-terminal which can disrupt processing. • Secretion validation: confirm conditioned media HGF levels by ELISA before functional assays. • Activation-deficient rescue: HGF requires HGFA (HGF activator) protease cleavage between α and β chains for biological activity — uncleavable HGF mutants generate latent/inactive HGF. • Functional readout: rescue should restore conditioned-media HGF levels and autocrine c-MET activation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FGF1 (fibroblast growth factor 1, acidic FGF)'s role as a pan-FGFR-activating growth factor or its emerging functions in metabolic disease therapy. The Knockout line is the standard tool for asking whether FGF1 is required for autocrine FGFR signaling — FGF1 is unique among FGFs in binding all four FGFR receptors (FGFR1-4) with high affinity, making it a 'universal' FGF ligand; FGF1 has emerged as a glucose-lowering hormone with insulin-like effects, attracting interest for diabetes therapeutic development. Overexpression is useful for studying FGF1 gain-of-function effects. For FGF-FGFR signaling research, the EDITGENE FGF1 Knockout in HEK293 enables study of autocrine FGF1 production. Rescue with wild-type or receptor-binding-deficient FGF1 enables structure-function studies. The knockout is valuable for studying FGF1-mediated metabolic effects, FGFR pan-activation biology, and emerging FGF1-based diabetes therapeutics (engineered FGF1 variants with reduced mitogenic activity but retained glucose-lowering).

Yes. FGF1 rescue experiments require attention to non-classical secretion: • Construct design: use a codon-modified FGF1 sequence with a small N-terminal tag (FLAG, HA) — FGF1 lacks a signal peptide and is secreted via a non-classical copper-mediated pathway under cellular stress; tag placement requires care. • Secretion validation: confirm conditioned media FGF1 levels by ELISA — FGF1 secretion is stress-induced (heat shock, hypoxia, serum starvation). • Heparin-binding-deficient rescue: FGF1ΔHBS (K127D/R133E/K134Q) abolishes heparin/HSPG binding but retains FGFR binding — useful for engineered FGF1 variants. • Non-mitogenic rescue: engineered FGF1 variants with reduced mitogenic activity but retained glucose-lowering enable separation of metabolic from proliferative effects. • Functional readout: rescue should restore conditioned-media FGF1 levels and autocrine FGFR activation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FAP (fibroblast activation protein, FAPα, seprase)'s role as a serine protease expressed on cancer-associated fibroblasts (CAFs) or modeling its applications in PET imaging and emerging FAP-targeted radioligand therapy. The Knockout line is the standard tool for asking whether FAP is required for these processes — FAP is a type II transmembrane serine protease (dipeptidyl peptidase activity, endopeptidase activity for gelatin/collagen) selectively expressed on CAFs in tumor stroma but minimally expressed in normal adult tissues; FAP is one of the most prominent emerging targets in cancer PET imaging, with 68Ga-FAPI (FAP-inhibitor) tracers showing superior tumor-to-background contrast compared to 18F-FDG in many cancers. Overexpression is useful for studying FAP in heterologous expression contexts. For cancer imaging and FAP-targeted therapy research, the EDITGENE FAP Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies of FAP and serves as a critical specificity control for FAP-targeted compound development. Rescue with wild-type or catalytically-dead FAP enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ 68Ga-FAPI-04, 68Ga-FAPI-46 (PET imaging tracers in widespread clinical use), Lu-177-FAPI radioligand therapy candidates, and emerging FAP-targeted therapeutic approaches (FAP-targeted CAR-T, anti-FAP antibodies). FAP-targeted PET imaging is considered one of the most significant advances in oncology imaging since 18F-FDG.

Yes. FAP rescue experiments are well-established for FAP-targeted compound research: • Construct design: use a codon-modified FAP sequence with a small intracellular N-terminal tag (FLAG, HA) — FAP is a type II transmembrane protein with short intracellular N-terminus, single transmembrane span, and large extracellular catalytic domain; N-terminal tag preserves catalytic domain integrity. • Surface localization validation: confirm plasma membrane localization by cell surface staining before FAPI tracer testing. • Catalytically-dead rescue: S624A (catalytic serine, active site) or H734A mutations abolish protease activity. • FAPI binding studies: rescue with WT FAP restores 68Ga-FAPI tracer binding and uptake — gold-standard specificity control for PET imaging tracer validation. • Functional readout: rescue should restore FAP enzymatic activity and FAPI tracer cellular accumulation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FBXW7's role as the principal F-box substrate receptor of the SCF^FBXW7 E3 ubiquitin ligase or modeling FBXW7-mutation-driven cancers. The Knockout line is the standard tool for asking whether FBXW7 is required for these processes — FBXW7 (FBW7, CDC4) is a tumor suppressor F-box protein that recognizes phosphodegron motifs (CPD, Cdc4 phosphodegron, T/S-P-X-X-S/T/E) on diverse substrates including MYC, Cyclin E, Notch1 ICD, Jun, mTOR, MCL1, SREBP1; FBXW7 is one of the most frequently mutated tumor suppressors in cancer (T-ALL, colorectal cancer, endometrial cancer, cholangiocarcinoma). Overexpression is useful for studying FBXW7 in heterologous expression contexts. For cancer biology research, the EDITGENE FBXW7 Knockout in HeLa is highly informative — FBXW7 loss stabilizes its substrates (MYC, Cyclin E, Notch1), driving proliferation and transformation. Rescue with wild-type or substrate-binding-deficient FBXW7 (e.g., R465H, R479Q, R505C hot-spot mutations in the WD40 substrate-binding domain) enables disease genotype-function studies of common cancer mutations. The knockout is valuable for studying substrate stability of MYC, Cyclin E, Notch1, mTOR pathway proteins, and emerging FBXW7-restored cancer therapeutic strategies.

Yes. FBXW7 rescue experiments are well-established for cancer ubiquitination research: • Construct design: use a codon-modified FBXW7 sequence with a small C-terminal tag (FLAG, HA). FBXW7 has N-terminal F-box (SKP1 binding) and C-terminal WD40 substrate-binding domain — preserve all elements. Three FBXW7 isoforms (α nuclear, β cytoplasmic, γ nucleolar) exist with distinct localizations. • Cancer mutation rescue: hot-spot mutations R465H, R479Q, R505C in the WD40 domain disrupt substrate phosphodegron binding — invaluable for studying common FBXW7 cancer mutations. • Substrate-binding-deficient rescue: WD40 domain mutations abolish substrate recognition without affecting SCF complex assembly. • Functional readout: rescue should restore MYC, Cyclin E, Notch1 degradation and reduce proliferative signaling. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying DDR2 (discoidin domain receptor 2)'s role as a collagen-activated receptor tyrosine kinase or modeling its functions in fibrosis, cancer, and skeletal dysplasia. The Knockout line is the standard tool for asking whether DDR2 is required for these processes — DDR1 and DDR2 constitute the discoidin domain receptor family, unique among RTKs in being activated by fibrillar collagens (DDR1 binds collagens I-V, VIII; DDR2 binds collagens I, II, III) rather than soluble growth factors; collagen binding induces slow, sustained DDR2 autophosphorylation. Overexpression is useful for studying DDR2 gain-of-function effects. For DDR2 research, the EDITGENE DDR2 Knockout in HCT 116 enables study of DDR2 biology in colorectal cancer context. DDR2 activating mutations are characteristic of squamous cell lung carcinoma (~4% of cases, e.g., L63V, S768R, I638F kinase domain mutations); DDR2 loss-of-function mutations cause spondylo-meta-epiphyseal dysplasia (SMED-SL/Al-Awadi-Teebi syndrome). Rescue with wild-type, kinase-dead, or disease-mutant DDR2 enables comprehensive structure-function studies. The knockout is a critical specificity tool for DDR2 inhibitors (dasatinib, imatinib have DDR2 activity; selective DDR2 inhibitors in development) and emerging anti-fibrosis therapeutics.

Yes. DDR2 rescue experiments are well-established for collagen receptor research: • Construct design: use a codon-modified DDR2 sequence with a small intracellular C-terminal tag (FLAG, HA). DDR2 has extracellular discoidin-like domain (collagen binding), discoidin-like domain 2, single transmembrane span, juxtamembrane region, and intracellular kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane localization before collagen binding studies. • Kinase-dead rescue: K608E mutation in the ATP-binding lysine abolishes catalytic activity. • Lung cancer mutation rescue: L63V, S768R, I638F mutations enable squamous cell lung carcinoma disease modeling. • Functional readout: rescue should restore collagen-induced phospho-DDR2 (Y740) signaling. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FTO (fat mass and obesity-associated)'s role as the principal m6A (N6-methyladenosine) RNA demethylase or modeling its functions in human colorectal cancer biology and metabolic disease. The Knockout line is the standard tool for asking whether FTO is required for these processes — FTO is a 2OG/Fe(II)-dependent dioxygenase that removes m6A from mRNA (and m1A from tRNA, m6Am from cap structures), making it one of two principal m6A 'erasers' (with ALKBH5); FTO common variants are the strongest human genetic association with obesity (T allele of rs9939609 increases obesity risk). Overexpression is useful for studying FTO in heterologous expression contexts. For colorectal cancer and m6A epitranscriptomics research, the EDITGENE FTO Knockout in HCT 116 is highly relevant — HCT 116 is a colorectal cancer cell line, and FTO has emerged as an oncogene in multiple cancers including colorectal cancer where m6A epitranscriptomic regulation drives proliferation. This product complements the parallel FTO Knockout in MAC-T (bovine mammary, also available) for human cancer versus agricultural genomics studies. Rescue with wild-type or catalytically-dead (H231A) FTO is the standard specificity control. The knockout is a critical specificity tool for FTO inhibitors (FB23-2, meclofenamic acid, R-2HG) and m6A-targeted cancer therapeutics.

Yes. FTO rescue experiments require attention to dioxygenase architecture: • Construct design: use a codon-modified FTO sequence with a small C-terminal tag (FLAG, HA). FTO has N-terminal AlkB-like dioxygenase domain and C-terminal β-helix domain — preserve all elements. • Catalytically-dead rescue: H231A or D233A active site Fe(II)-coordinating residue mutations abolish demethylase activity and serve as the standard specificity control. • Functional readout: rescue should restore m6A demethylase activity measured by global mRNA m6A levels (LC-MS) or m6A-RIP-seq. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FOXN3's role in a complementary lung cancer background for cross-validation of FOXN3-dependent phenotypes. The Knockout line is the standard tool for asking whether FOXN3 is required for these processes in NSCLC context. Overexpression is useful for studying FOXN3 gain-of-function effects. For lung cancer research, the EDITGENE FOXN3 Knockout in A-549 enables study of FOXN3 in NSCLC context. This product complements the parallel FOXN3 Knockout in Hep-G2 (also available); cross-background validation strengthens characterization of FOXN3-dependent phenotypes. Rescue with wild-type FOXN3 is the standard specificity control. The knockout is valuable for studying FOXN3 in lung cancer biology.

Yes. FOXN3 rescue experiments in A-549 are well-suited for cross-validation: • Construct design: same considerations as FOXN3/Hep-G2 rescue — preserve forkhead DNA-binding domain. • Cross-background comparison: rescue in A-549 alongside Hep-G2 enables confirmation of context-independent FOXN3 functions. • Functional readout: rescue should restore FOXN3-dependent phenotypes identified during knockout characterization. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CTH (cystathionine γ-lyase, CSE)'s role in transsulfuration and H₂S biosynthesis or modeling its functions in lung cancer and cysteine metabolism. The Knockout line is the standard tool for asking whether CTH is required for these processes — CTH catalyzes the second step of transsulfuration (cystathionine → cysteine + α-ketobutyrate + NH₃), generating cysteine from methionine-derived homocysteine; CTH is also one of three enzymes (with CBS and 3-MST) that generates H₂S, an endogenous gaseous signaling molecule with cardiovascular and anti-inflammatory effects. Overexpression is useful for studying CTH gain-of-function effects. For lung cancer and metabolic research, the EDITGENE CTH Knockout in A-549 is highly relevant — A-549 is an NSCLC cell line, and CTH-derived cysteine/H₂S has been implicated in NSCLC biology including glutathione synthesis and redox balance. Rescue with wild-type or catalytically-dead CTH enables structure-function studies. CTH biallelic loss causes cystathioninuria (autosomal recessive metabolic disorder). The knockout is valuable for studying transsulfuration biology, H₂S signaling, ferroptosis (cysteine availability for GSH synthesis), and emerging CTH-targeted approaches.